Hidradenitis suppurativa Trials in Barcelona, Spain
Conditions / Hidradenitis suppurativa / Barcelona, Spain
Clinical trials for Hidradenitis suppurativa investigate a range of treatment strategies and patient populations.
26 total trials for this combination
Showing top 10 of 26 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06959225 | Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) | RECRUITING | — |
| NCT04901195 | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | — |
| NCT06799000 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1) | RECRUITING | PHASE3 |
| NCT06840392 | A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa | RECRUITING | PHASE3 |
| NCT05889182 | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy | RECRUITING | PHASE3 |
| NCT05819398 | Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa | COMPLETED | PHASE2/PHASE3 |
| NCT04901195 | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | — |
| NCT03661866 | A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC | RECRUITING | — |
| NCT04179175 | Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03713619 | This Was a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS). | COMPLETED | PHASE3 |